Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. The companies ...
Please provide your email address to receive an email when new articles are posted on . The companies will work together to develop sustained-release ophthalmic therapies. The deal has a potential ...
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results